The main catalyst stayed on schedule, rather than moving forward. The last participant completed the 16-week blinded portion of the 78-person Phase 3 LUCIDITY trial, with topline data still expected in late August or early September 2026 (Upcoming Expected Milestones). That is a confirmation of the prior Q3 2026 timeline, not a new acceleration; the readout itself remains the decisive event for avexitide and is now only weeks away.
| Metric | Q2 2026 | Q2 2025 / reference | Read |
|---|---|---|---|
| Net loss | $43.4 million | $41.4 million | Loss widened (Income Statement) |
| Loss per share | $0.39 | $0.46 | Smaller per-share loss, helped by share-count growth (Income Statement) |
| Published consensus loss per share | — | — | Approximately $0.36–$0.37 loss per share; actual result was modestly worse. |
| R&D expense | $23.8 million | $27.2 million | Lower as discontinued/curtailed PSP spending offset higher avexitide costs (Financial Results) |
| SG&A expense | $21.9 million | $15.6 million | Up 40% as commercial preparation and legal costs increased (Financial Results) |
| Cash, equivalents and short-term investments | $250.8 million | $279.8 million at March 31, 2026 | $29.0 million quarterly decline; runway still projected into 2028 (Balance Sheets; Cash Position) |
The financial quarter was slightly worse than the standing earnings bar. Amylyx reported a $0.39 per-share loss versus a published consensus near $0.36–$0.37, a narrow miss rather than a major cost-control failure. The underlying mix is less favorable than the headline per-share improvement suggests: R&D fell as older PSP work declined, while SG&A rose sharply because the company is spending more on commercial readiness and legal matters (Financial Results; Income Statement). The higher weighted-average share count also helped reduce the loss per share year over year (Income Statement).
Cash remains sufficient for the near-term binary event, but spending is accelerating commercially. Cash and short-term investments fell from $279.8 million at March 31, 2026 to $250.8 million at June 30, 2026, while SG&A increased to $21.9 million as Amylyx prepared for a potential 2027 avexitide launch (Cash Position; Financial Results). Management still expects funding into 2028, so the filing does not create an immediate financing concern; however, the cash position makes the upcoming LUCIDITY result increasingly central to the company’s value proposition.
Net read: modestly negative on the quarter, unchanged on the pivotal timeline. The only clear expectation gap is the small EPS miss. The clinically important update—completion of the blinded treatment period and an imminent topline readout—was broadly already anticipated, so it adds execution confirmation but not incremental evidence that avexitide works. The filing therefore leaves the investment case largely dependent on whether LUCIDITY produces the expected reduction in Level 2 and Level 3 hypoglycemic events (About the LUCIDITY Trial; Upcoming Expected Milestones).
Read the original 8-K on SEC EDGAR ↗